This table presents recent patent oppositions filed by Bioverativ Therapeutics Inc. against its competitors. It outlines key details of each case, including the patent title, filing date and the applicant. This information provides insights into the competitive landscape and highlights active disputes over patent grant within the industry.

Patent NumberTitleApplicantOpposition Date
EP3225233Sodium Chloride Solution For Drug Reconstitution Or DilutionWYETH LLCMay 14, 2020
EP2482841Compositions And Methods For Enhancing Coagulation Factor Viii FunctionTHE CHILDREN'S HOSPITAL OF PHILADELPHIAAug 21, 2019

The following table provides an overview of the latest patents of Bioverativ Therapeutics Inc. that has been opposed by its competitors. It provides an insight into the competitive landscape of the industry and highlights the patents that are subject to oppositions.

Patent NumberGrant DateTitleTotal Oppositions
EP2956477Jan 24, 2024Optimized Factor Viii Gene1
EP2870250Jun 29, 2022Cell Line Expressing Single Chain Factor Viii Polypeptides And Uses Thereof2